Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease

Neuroscience Bulletin

Volumn 27, Issue 4, 2011, Pages 221-232

  Xiong, Huaqi ^a   Callaghan, Debbie ^a   Wodzinska, Jolanta ^b   Xu, Jiejing ^b   Premyslova, Maryna ^b   Liu, Qing Yan ^a   Connelly, John ^b   Zhang, Wandong ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b ApoPharma Inc   (Canada)

Author keywords

amyloid peptides; Alzheimer's disease; behavioral test; DNA oxidative damage; Mouse model; Secretase activities

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; SECRETASE;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; FROZEN SECTION; GENOTYPE; HEMISPHERE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; OXIDATIVE STRESS; PS1 GENE; TISSUE DISTRIBUTION; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; DEOXYGUANOSINE; DISEASE MODELS, ANIMAL; HUMANS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS;

EID: 80755125653     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-011-1015-7     Document Type: Article

References (17)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81: 741-766. (Pubitemid 32267077)
2. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003, 43: 545-584. (Pubitemid 37372653)
3. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004, 13(2): 159-170. (Pubitemid 38111354)
4. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19 (4): 939-945. (Pubitemid 27471397)
5. Mojsilovic-Petrovic J, Callaghan D, Cui H, Dean C, Stanimirovic DB, Zhang W. Hypoxia-inducible factor-1 (HIF-1) is involved in the regulation of hypoxia-stimulated expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) and MCP-5 (Ccl12) in astrocytes. J Neuroinflammation 2007, 4: 12.
6. Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, et al. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 2004, 1012(1-2): 29-41. (Pubitemid 38648896)
7. Leighty RE, Nilsson LN, Potter H, Costa DA, Low MA, Bales KR, et al. Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behav Brain Res 2004, 153(1): 107-121. (Pubitemid 38829294)
8. Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, et al. ABCG2 is up-regulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for A?1-40 peptides. J Neurosci 2009, 29 (17): 5463-5475.
9. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, et al. Cholesterol retention in Alzheimer's brain is responsible for high ?- and ?-secretase activities and Abeta production. Neurobiol Dis 2008, 29 (3): 422-437.
10. Komano H, Rockwell N, Wang GT, Krafft GA, Fuller RS. Purification and characterization of the yeast glycosylphosphatidylinositolanchored, monobasic-specific aspartyl protease yapsin 2 (Mkc7p). J Biol Chem 1999, 274(34): 24431-24437.
11. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192(1): 106-113.
12. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39(3): 409-421. (Pubitemid 36937044)
13. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 2009, 34: 95-106.
14. Walker DG, Lue LF, Beach TG. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging 2001, 22: 957-966. (Pubitemid 34066564)
15. Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE. Gene expression changes by amyloid beta peptide-stimulated human post mortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 2006, 79: 589-610.
16. Zlokovic VB. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57: 178-201.
17. Shen S, Zhang W. ABC transporters and drug efflux at the bloodbrain barrier. Reviews in Neurosci 2010, 21(1): 29-53.